SY-001 is under development for the treatment of advanced solid tumors including advanced ovarian cancer and pancreatic cancer. It comprises of induced pluripotent stem cells derived macrophages which ...

Heartseed Inc. and Novo Nordisk - in partnership since June 2021 - have announced that the first patient has been successfully dosed in a clinical study with HS-001, a cell therapy designed to ...